European Molecular Biology Laboratory acquires 16.2% stake in Veraxa Biotech via business combination
European Molecular Biology Laboratory acquired 22,891,235 ordinary shares of Veraxa Biotech Holding AG, representing 16.2% of the class, in connection with the closing of a business combination. The shares carry shared voting and dispositive power. The holder is party to a Voting, Support and Lock-Up Agreement restricting transfers for a specified period, and company shareholders are eligible to receive up to 5,000,000 additional earnout shares per fiscal year through December 31, 2028, contingent on specified volume-weighted average price thresholds.
Key facts
- 22,891,235 ordinary shares acquired
- 16.2% of class held with shared voting and dispositive power
- Voting, Support and Lock-Up Agreement restricts transfers for specified period
- Earnout shares eligible: up to 5,000,000 per fiscal year through December 31, 2028
- VWAP thresholds: $11.00 by December 31, 2026; $12.50 by December 31, 2027; $14.00 by December 31, 2028
- Acquired in connection with business combination closing
Why it matters
EMBL's substantial stake and transfer restrictions lock it into Veraxa for a material period, while earnout provisions tie additional share issuance to specific stock-price milestones over three years, affecting dilution timing and ownership structure.
Share
Derived from SCHEDULE 13D filed 2026-06-16. Not investment advice. View the source filing on SEC.gov →